CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Director Wei-Wu He purchased 100,000 shares of the firm’s stock in a transaction dated Tuesday, October 10th. The stock was bought at an average cost of $1.95 per share, with a total value of $195,000.00. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Wei-Wu He also recently made the following trade(s):

  • On Friday, October 6th, Wei-Wu He bought 200,000 shares of CASI Pharmaceuticals stock. The shares were acquired at an average price of $1.83 per share, for a total transaction of $366,000.00.
  • On Monday, September 18th, Wei-Wu He bought 173,500 shares of CASI Pharmaceuticals stock. The shares were acquired at an average price of $1.75 per share, for a total transaction of $303,625.00.
  • On Tuesday, September 19th, Wei-Wu He bought 207,502 shares of CASI Pharmaceuticals stock. The shares were acquired at an average price of $1.75 per share, for a total transaction of $363,128.50.
  • On Friday, September 15th, Wei-Wu He bought 315,327 shares of CASI Pharmaceuticals stock. The shares were acquired at an average price of $1.33 per share, for a total transaction of $419,384.91.

CASI Pharmaceuticals (NASDAQ:CASI) last posted its quarterly earnings data on Monday, August 14th. The biotechnology company reported ($0.04) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.03) by ($0.01).

WARNING: This piece of content was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of US and international copyright law. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/10/13/wei-wu-he-acquires-100000-shares-of-casi-pharmaceuticals-inc-casi-stock.html.

Several equities research analysts recently commented on the company. ValuEngine upgraded CASI Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, September 15th. HC Wainwright restated a “buy” rating and set a $2.00 target price on shares of CASI Pharmaceuticals in a research report on Friday, September 8th. Finally, Maxim Group restated a “buy” rating and set a $4.00 target price on shares of CASI Pharmaceuticals in a research report on Friday, September 8th.

CASI Pharmaceuticals Company Profile

CASI Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development.

Receive News & Stock Ratings for CASI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.